A detailed history of Bank Of America Corp transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 117,343 shares of PSTX stock, worth $320,346. This represents 0.0% of its overall portfolio holdings.

Number of Shares
117,343
Previous 94,294 24.44%
Holding current value
$320,346
Previous $275,000 21.82%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.7 - $4.04 $62,232 - $93,117
23,049 Added 24.44%
117,343 $335,000
Q2 2024

Aug 14, 2024

SELL
$2.0 - $3.46 $180,144 - $311,649
-90,072 Reduced 48.85%
94,294 $275,000
Q1 2024

May 15, 2024

SELL
$2.76 - $4.13 $146,981 - $219,939
-53,254 Reduced 22.41%
184,366 $588,000
Q4 2023

Feb 14, 2024

SELL
$1.83 - $3.51 $172,762 - $331,365
-94,406 Reduced 28.43%
237,620 $798,000
Q2 2023

Aug 14, 2023

BUY
$1.66 - $3.4 $132,597 - $271,585
79,878 Added 31.68%
332,026 $584,000
Q1 2023

May 12, 2023

BUY
$3.08 - $8.73 $719,032 - $2.04 Million
233,452 Added 1248.67%
252,148 $776,000
Q4 2022

Feb 10, 2023

SELL
$3.33 - $6.38 $25,264 - $48,405
-7,587 Reduced 28.87%
18,696 $99,000
Q3 2022

Nov 14, 2022

BUY
$2.43 - $4.51 $8,466 - $15,712
3,484 Added 15.28%
26,283 $92,000
Q2 2022

Aug 12, 2022

SELL
$1.87 - $5.0 $16,736 - $44,750
-8,950 Reduced 28.19%
22,799 $58,000
Q1 2022

May 16, 2022

SELL
$3.22 - $7.04 $5,068 - $11,080
-1,574 Reduced 4.72%
31,749 $143,000
Q4 2021

Feb 08, 2022

BUY
$6.23 - $7.6 $25,468 - $31,068
4,088 Added 13.98%
33,323 $227,000
Q3 2021

Nov 15, 2021

BUY
$7.09 - $10.71 $23,992 - $36,242
3,384 Added 13.09%
29,235 $213,000
Q2 2021

Sep 13, 2021

BUY
$7.96 - $10.07 $205,773 - $260,319
25,851 New
25,851 $259,000

Others Institutions Holding PSTX

About Poseida Therapeutics, Inc.


  • Ticker PSTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 85,775,600
  • Market Cap $234M
  • Description
  • Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...
More about PSTX
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.